Literature DB >> 12821040

Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease.

Kim Brinch1, Søren Møller, Flemming Bendtsen, Ulrik Becker, Jens H Henriksen.   

Abstract

BACKGROUND/AIMS: The aim of the study was to investigate the effect of a standard albumin load on blood volume distribution, arterial compliance, and the renin-angiotensin-aldosterone system in patients with different degrees of cirrhosis.
METHODS: 31 patients with cirrhosis (Child classes A/B/C=8/14/9) received an intravenous infusion of 40 g human serum albumin during a haemodynamic investigation.
RESULTS: Whereas plasma- and blood volume increased by 23 and 15%, respectively (P<0.001), a significant increase in central blood volume was found only in class A patients (+8%, P<0.05), but not in class B or class C patients (+2.7%, not significant (n.s.)). In contrast, arterial compliance only increased significantly in class C patients (+18%, P<0.05), but not in class A or class B patients (+6%, n.s.). Plasma renin activity (PRA) decreased significantly in class C patients (-31%, P<0.05). When all patients were compared, the change in arterial compliance was inversely correlated to the change in PRA (r=-0.50, P<0.01).
CONCLUSIONS: Although infusion of albumin does not expand the central blood volume in patients with advanced cirrhosis, the results indicate a significant improvement in the low effective arterial blood volume of such patients, which may be important in the prevention of circulatory dysfunction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12821040     DOI: 10.1016/s0168-8278(03)00160-0

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  22 in total

Review 1.  Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.

Authors:  Francesco Salerno; Alexander Gerbes; Pere Ginès; Florence Wong; Vicente Arroyo
Journal:  Gut       Date:  2007-03-27       Impact factor: 23.059

Review 2.  Liver cirrhosis and arterial hypertension.

Authors:  Jens H Henriksen; Soren Moller
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

Review 3.  Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects.

Authors:  Søren Møller; Jens H Henriksen; Flemming Bendtsen
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 4.  Cirrhotic Multiorgan Syndrome.

Authors:  Søren Møller; Flemming Bendtsen
Journal:  Dig Dis Sci       Date:  2015-06-26       Impact factor: 3.199

Review 5.  Hypertension and liver disease.

Authors:  Jens H Henriksen; Søren Møller
Journal:  Curr Hypertens Rep       Date:  2004-12       Impact factor: 5.369

6.  Contribution of diuretic therapy with human serum albumin to the management of ascites in patients with advanced liver cirrhosis: A prospective cohort study.

Authors:  Toru Nakamura; Michio Sata; Kazumasa Hiroishi; Naohiko Masaki; Hisataka Moriwaki; Yoshikazu Murawaki; Hiroshi Yatsuhashi; Shigetoshi Fujiyama; Michio Imawari
Journal:  Mol Clin Oncol       Date:  2014-01-16

Review 7.  Cardiopulmonary complications in chronic liver disease.

Authors:  Soren Moller; Jens H Henriksen
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

8.  Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial.

Authors:  Roberto-Giulio Romanelli; Giorgio La Villa; Giuseppe Barletta; Francesco Vizzutti; Fabio Lanini; Umberto Arena; Vieri Boddi; Roberto Tarquini; Pietro Pantaleo; Paolo Gentilini; Giacomo Laffi
Journal:  World J Gastroenterol       Date:  2006-03-07       Impact factor: 5.742

9.  Arterial hypertension in cirrhosis: arterial compliance, volume distribution, and central haemodynamics.

Authors:  J H Henriksen; S Fuglsang; F Bendtsen; S Møller
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

Review 10.  Diastolic dysfunction in cirrhosis.

Authors:  Søren Møller; Signe Wiese; Hanne Halgreen; Jens D Hove
Journal:  Heart Fail Rev       Date:  2016-09       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.